Výsledky vyhledávání - "Evan J. Friedman"

Lack of a Clinically Meaningful Drug Interaction Between the HIV‐1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate

Autor: Danielle Armas, Sabrina Fox-Bosetti, Saijuan Zhang, Deanne Jackson Rudd, Evan J. Friedman, Randolph P. Matthews, Kerry L. Fillgrove, S. Aubrey Stoch, Marian Iwamoto

Publikováno v: Clinical Pharmacology in Drug Development. 10:1432-1441

Islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, is in clinical development for the treatment and prevention of HIV-1 infection. Because islatravir may be coadministered with other antiretroviral agents, assess

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613138de38c4a22f5159325aa9310e8a
https://doi.org/10.1002/cpdd.1026

Zobrazit plný text záznamu

Single Oral Doses of MK-8507, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor, Suppress HIV-1 RNA for a Week

Autor: Martin Daumer, Wendy Ankrom, Deanne Jackson Rudd, Yang Liu, Dirk Schürmann, Jörg Hofmann, Marian Iwamoto, Inge De Lepeleire, Christian Keicher, Evan J. Friedman, Martine Robberechts, Andrea K. Schaeffer, S. Aubrey Stoch, Jay A. Grobler, Bhargava Kandala, Saijuan Zhang

Publikováno v: Journal of Acquired Immune Deficiency Syndromes (1999)

Background MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor being developed for treatment of HIV-1 infection. MK-8507 has high antiviral potency in vitro and pharmacokinetic (PK) properties that support once-weekly dosing. Sett

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8d822287e947e4275e511e6e9962a10
http://europepmc.org/articles/PMC8740605

Zobrazit plný text záznamu

Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV

Autor: Andrea K. Schaeffer, Deborah Panebianco, Charles Tomek, Deanne Jackson Rudd, S. Aubrey Stoch, Marian Iwamoto, Wendy Ankrom, Evan J. Friedman

Publikováno v: Antimicrobial Agents and Chemotherapy

MK-8507 is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor in clinical development with potential for once-weekly oral administration for the treatment of HIV-1 infection. Two randomized, double-blind, placebo-controlled phase 1 studies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b222a8f29a199906775fe0c7b5fa4dc2
https://pubmed.ncbi.nlm.nih.gov/34516246

Zobrazit plný text záznamu

Safety, tolerability, and pharmacokinetics of single- and multiple-dose administration of islatravir (MK-8591) in adults without HIV

Autor: Deborah Panebianco, Magdalena Petkova, Deanne Jackson Rudd, Robin Mogg, Inge De Lepeleire, Jay A. Grobler, Evan J. Friedman, Wendy Ankrom, Selwyn Aubrey Stoch, Marian Iwamoto, Randolph P. Matthews, Yang Liu

Publikováno v: Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 5, Pp 1935-1944 (2021)

Islatravir (MK‐8591) is a nucleoside analogue in development for the treatment and prevention of HIV‐1. Two phase 1 trials were conducted during initial evaluation of islatravir: rising single doses (Study 1) and rising multiple doses (Study 2) o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d0b6886d7ad5ca92cf112f42143c04c
https://pubmed.ncbi.nlm.nih.gov/34463432

Zobrazit plný text záznamu

Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants

Autor: Elizabeth G. Rhee, Mallika Lala, Evan J. Friedman, Yang Liu, Keith Boundy, Matthew L. Rizk, Terry O'Reilly, Francheska Colon-Gonzalez, Pratik Bhagunde

Publikováno v: Clinical pharmacology in drug developmentReferences. 9(4)

The effects of supratherapeutic doses of intravenous (IV) relebactam on duration of ventricular depolarization and subsequent repolarization were assessed in a thorough QT/corrected QT study. This was a single-dose, double-blind (relebactam only), ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb705b65483a0e7558f4e526cb0bae47
https://pubmed.ncbi.nlm.nih.gov/32212418

Zobrazit plný text záznamu

Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men

Autor: Yuki Matsumoto, Saori Tsuchiya, Carol Addy, Eunkyung Kauh, Daniel Tatosian, Evan J. Friedman, Akira Wakana, Hideyo Suzuki

Publikováno v: Journal of Diabetes Investigation

Aims/Introduction Omarigliptin is a novel, potent, long-acting oral dipeptidyl peptidase-4 inhibitor being developed as a once-weekly (q.w.) treatment for type 2 diabetes mellitus patients, with 25 mg and 12.5 mg tablets recently being approved as ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0891c4a4ff742949eaba6fbb175fca30
https://doi.org/10.1111/jdi.12538

Zobrazit plný text záznamu

Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir

Autor: John McDermott, Pranav Gupta, Philip Evans, Rajesh Krishna, Filippos Kesisoglou, Valerie Schulz, Ronald D. Smith, Evan J. Friedman, Patrick Larson, Matthew L. Rizk, Alyson Connor

Publikováno v: Therapeutic innovationregulatory science. 50(6)

Raltegravir is an integrase strand transfer inhibitor indicated in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infection, given twice daily. Although a BCS class II compound, raltegravir exhibits low colonic a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::781acbbf445ee39639074329ceda96ea
https://pubmed.ncbi.nlm.nih.gov/30231748

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání